Literature DB >> 29299417

The reproducibility of PD-L1 scoring in lung cancer: can the pathologists do better?

Giancarlo Troncone1, Cesare Gridelli2.   

Abstract

Entities:  

Year:  2017        PMID： 29299417      PMCID： PMC5750142          DOI： 10.21037/tlcr.2017.10.05

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  10 in total

1.  Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC.

Authors:  Jan Trøst Jørgensen
Journal:  Expert Rev Mol Diagn       Date:  2015-11-27       Impact factor: 5.225

Review 2.  Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.

Authors:  Cesare Gridelli; Andrea Ardizzoni; Massimo Barberis; Federico Cappuzzo; Francesca Casaluce; Romano Danesi; Giancarlo Troncone; Filippo De Marinis
Journal:  Transl Lung Cancer Res       Date:  2017-06

3.  Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer.

Authors:  Wendy A Cooper; Prudence A Russell; Maya Cherian; Edwina E Duhig; David Godbolt; Peter J Jessup; Christine Khoo; Connull Leslie; Annabelle Mahar; David F Moffat; Vanathi Sivasubramaniam; Celine Faure; Alena Reznichenko; Amanda Grattan; Stephen B Fox
Journal:  Clin Cancer Res       Date:  2017-04-18       Impact factor: 12.531

4.  PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability.

Authors:  Hans Brunnström; Anna Johansson; Sofia Westbom-Fremer; Max Backman; Dijana Djureinovic; Annika Patthey; Martin Isaksson-Mettävainio; Miklos Gulyas; Patrick Micke
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

Review 5.  ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.

Authors:  Pasquale Pisapia; Maria D Lozano; Elena Vigliar; Claudio Bellevicine; Francesco Pepe; Umberto Malapelle; Giancarlo Troncone
Journal:  Cancer Cytopathol       Date:  2017-07-25       Impact factor: 5.284

6.  Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.

Authors:  Andreas H Scheel; Manfred Dietel; Lukas C Heukamp; Korinna Jöhrens; Thomas Kirchner; Simone Reu; Josef Rüschoff; Hans-Ulrich Schildhaus; Peter Schirmacher; Markus Tiemann; Arne Warth; Wilko Weichert; Rieke N Fischer; Jürgen Wolf; Reinhard Buettner
Journal:  Mod Pathol       Date:  2016-07-08       Impact factor: 7.842

7.  A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.

Authors:  David L Rimm; Gang Han; Janis M Taube; Eunhee S Yi; Julia A Bridge; Douglas B Flieder; Robert Homer; William W West; Hong Wu; Anja C Roden; Junya Fujimoto; Hui Yu; Robert Anders; Ashley Kowalewski; Christopher Rivard; Jamaal Rehman; Cory Batenchuk; Virginia Burns; Fred R Hirsch; Ignacio I Wistuba
Journal:  JAMA Oncol       Date:  2017-08-01       Impact factor: 31.777

8.  Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer.

Authors:  Jamaal A Rehman; Gang Han; Daniel E Carvajal-Hausdorf; Brad E Wasserman; Vasiliki Pelekanou; Nikita L Mani; Joseph McLaughlin; Kurt A Schalper; David L Rimm
Journal:  Mod Pathol       Date:  2016-11-11       Impact factor: 7.842

9.  FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.

Authors:  Lee Pai-Scherf; Gideon M Blumenthal; Hongshan Li; Sriram Subramaniam; Pallavi S Mishra-Kalyani; Kun He; Hong Zhao; Jingyu Yu; Mark Paciga; Kirsten B Goldberg; Amy E McKee; Patricia Keegan; Richard Pazdur
Journal:  Oncologist       Date:  2017-08-23

10.  Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer.

Authors:  Charlotte Roach; Nancy Zhang; Ellie Corigliano; Malinka Jansson; Grant Toland; Gary Ponto; Marisa Dolled-Filhart; Kenneth Emancipator; Dave Stanforth; Karina Kulangara
Journal:  Appl Immunohistochem Mol Morphol       Date:  2016-07
  10 in total
  5 in total

1.  A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging.

Authors:  Leeat Keren; Marc Bosse; Diana Marquez; Roshan Angoshtari; Samir Jain; Sushama Varma; Soo-Ryum Yang; Allison Kurian; David Van Valen; Robert West; Sean C Bendall; Michael Angelo
Journal:  Cell       Date:  2018-09-06       Impact factor: 41.582

2.  Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression.

Authors:  Kyriakos Chatzopoulos; Andrea R Collins; Sotiris Sotiriou; Michael G Keeney; Daniel W Visscher; Michael Rivera; David J Schembri-Wismayer; Jean E Lewis; Patricia T Greipp; William R Sukov; Ashish V Chintakuntlawar; Katharine A Price; Joaquin J Garcia
Journal:  Head Neck Pathol       Date:  2020-04-29

Review 3.  Precision immunoprofiling by image analysis and artificial intelligence.

Authors:  Viktor H Koelzer; Korsuk Sirinukunwattana; Jens Rittscher; Kirsten D Mertz
Journal:  Virchows Arch       Date:  2018-11-23       Impact factor: 4.064

Review 4.  Multiplex Immunofluorescence and Multispectral Imaging: Forming the Basis of a Clinical Test Platform for Immuno-Oncology.

Authors:  Clifford C Hoyt
Journal:  Front Mol Biosci       Date:  2021-06-02

Review 5.  Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise.

Authors:  Brian Healey Bird; Ken Nally; Karine Ronan; Gerard Clarke; Sylvie Amu; Ana S Almeida; Richard Flavin; Stephen Finn
Journal:  Diagnostics (Basel)       Date:  2022-01-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.